Global Biopsy Market is anticipated to reach US$ 40.09 Bn by 2027 from US$ 21.23 Bn in 2019 at a CAGR of 11.14% during a forecast period.
Global Biopsy Market Overview
Biopsies have made significant advances in molecular medicine, particularly in cancer. The molecular characterization of malignancies has been improved because of technological advancements in the equipment used for biopsies. They’ve been widely utilized to diagnose cancer, determine the tumor’s structure, and determine the cancer stage. The development of molecular tests is critical to the evolution of the cancer biopsy market. Biopsies are utilized in clinical studies to evaluate medication response rates, particularly in patients receiving epidermal growth factor receptor (EGFR) therapy.
To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2019 is considered a base year however 2020’s numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.
Global Biopsy Market Dynamics
The increased use of liquid biopsies, a non-invasive approach that provides advantages over other processes, helps market growth. Are all examples of oncology biologists covering a variety of procedures, such as skin biopsy, needles biopsy, bone marrow biopsy, surgical biopsy, and other types of biopsy. Bone diagnosis is a comprehensive and complex type of diagnostic method. In March 2021, for instance, the U.S. FDA appointed RaDaR as a breakthrough device to detect the lowest amount of residual illness in early-stage cancer. Fine needle aspiration biopsies are an emerging technology that is increasingly being used in several forms of cancer, most notably breast cancer, lung cancer, colorectal cancer, blood cancer, and thyroid cancer. The advantages of multi-parametric magnetic resonance (MR) imaging-based biopsies are driving their increasing popularity. The rising use of image-guided needle biopsies in precision medicine is a significant market trend, which is expected to drive the growth of the market.
Global Biopsy Market Segmentation Analysis
By Product, Kits and consumables accounted for more than 60.0 percent of sales in 2019 since they are essential throughout the various phases of biopsies. Additionally, considerable expenditures by major companies in this industry have contributed significantly to segment growth.
By Application, in 2019, breast biopsy held the highest share of over 14.0 percent. The most common type of cancer is breast cancer. According to U.S. breast cancer statistics, around one in every eight women in the United States develops invasive breast cancer. in 2020, an estimated 276,480 new instances of invasive breast cancer in the United States are expected to be identified in women, with more than 40,000 new cases of non-invasive breast cancer.
Global Biopsy Market Regional Insights
In 2019, North America had the largest share of more than 40.0 percent. The region is expected to maintain its lead throughout the forecast period, with the United States contributing significantly to regional revenue. The cancer biopsy market in the United States is expected to reach USD 15.98 billion by 2027, growing at a CAGR of 11.0 percent during the forecast period. One of the main reasons driving the market is the growing use of technologically advanced devices for illness early detection. Distributors and manufacturers in this region also want to create new kits that are well-suited for fast diagnostic applications. Asia Pacific is expected to grow at a CAGR of xx% during the forecast period. Its popularity has risen in parallel with increased public awareness of cancer’s morbidity. The high frequency of breast cancer has driven demand for biopsies, and advantageous reimbursement and payer networks are boosting the region’s global cancer biopsy market growth potential.
Global Biopsy Market Scope: Inquire before buying
Global Biopsy Market by Region
• North America • Asia pacific • Europe • Middle East and Africa • South America
Global Biopsy Market Key Players
• Qiagen N.V. • Illumina, Inc. • ANGLE Plc • BD (Becton, Dickinson and Company) • Myriad Genetics • Hologic, Inc. • Biocept, Inc. • Thermo Fisher Scientific, Inc. • Danaher • F. Hoffmann-La Roche Ltd. • Lucence Diagnostics Pte. Ltd. • GRAIL, Inc. • Guardant Health • Exact Sciences Corporation • Freenome Holdings, Inc. • Biodesix (Integrated Diagnostics) • Oncimmune • Epigenomics AG • HelioHealth (Laboratory for Advanced Medicine) • Genesystems, Inc. (Genesys Biolabs)
Frequently Asked Questions
1. What is the projected market size growth rate of the Global Biopsy Market? Ans- Biopsy Market was valued at USD 21.23 billion in 2019 and is projected to reach USD 40.09 billion by 2027, growing at a CAGR of 11.14% during the forecast period. 2. What is the key driving factor for the growth of the Global Biopsy Market? Ans- The increased use of liquid biopsies, a non-invasive approach that provides advantages over other processes, helps market growth. 3. Which region accounted for the largest Global Biopsy Market share? Ans- In 2019, North America had the largest share of more than 40.0 percent. 4. What makes the Asia Pacific a Lucrative Market for Global Biopsy Market? Ans- The high frequency of breast cancer has driven demand for biopsies, and advantageous reimbursement and payer networks are boosting the region’s global cancer biopsy market growth potential. 5. What are the top players operating in the Global Biopsy Market? Ans-Qiagen N.V., Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson and Company), Myriad Genetics, Hologic, Inc., Biocept, Inc., and Thermo Fisher Scientific, I
